Retraction notice to ”Clomiphene citrate or anastrozole for ovulation induction in women with polycystic ovary syndrome? A prospective controlled trial”
Retraction notice to “Clomiphene citrate or anastrozole for ovulation induction in women with polycystic ovary syndrome? A prospective controlled trial” (Source: Fertility and Sterility)
Source: Fertility and Sterility - July 29, 2023 Category: Reproduction Medicine Tags: Retractions Source Type: research
Sex steroids regulate liver fat content and body fat distribution in both men and women: a study in transgender persons
CONCLUSIONS: Sex hormones regulate liver fat content and visceral fat in men and women.PMID:37463488 | DOI:10.1210/clinem/dgad409 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - July 18, 2023 Category: Endocrinology Authors: Marieke Tebbens Moya Schutte Marian A Troelstra Eveline Bruinstroop Ren ée de Mutsert Aart J Nederveen Martin den Heijer Peter H Bisschop Source Type: research
Testosterone and Luteinizing Hormone Predict Semen Parameter Improvement in Infertile Men Treated with Anastrozole
Capsule (30-word max): Semen parameters improve in half of infertile men treated with anastrozole. Treatment response is best predicted by baseline non-azoospermia and a pre-treatment ratio of testosterone to luteinizing hormone ≥100. (Source: Fertility and Sterility)
Source: Fertility and Sterility - June 29, 2023 Category: Reproduction Medicine Authors: Bryan D. Naelitz, Tommy Jiang, Carlos Munoz-Lopez, John Tucker Sigalos, Neilufar Modiri, Rosella Cannarella, Jesse Mills, Neel Parekh, Amy S. Nowacki, Sarah C. Vij, Sriram V. Eleswarapu, Scott D. Lundy Tags: Andrology Source Type: research
Erratum: Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
J Clin Oncol. 2023 Jun 26:JCO2301230. doi: 10.1200/JCO.23.01230. Online ahead of print.NO ABSTRACTPMID:37364217 | DOI:10.1200/JCO.23.01230 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - June 26, 2023 Category: Cancer & Oncology Source Type: research
Erratum: Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
J Clin Oncol. 2023 Jun 26:JCO2301230. doi: 10.1200/JCO.23.01230. Online ahead of print.NO ABSTRACTPMID:37364217 | DOI:10.1200/JCO.23.01230 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 26, 2023 Category: Cancer & Oncology Source Type: research
Molecules, Vol. 28, Pages 4893: In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment
Conclusions: This is the first in vitro study that highlights the potential benefit of G as an adjuvant therapy with Exe, emphasizing, however, that soy derivatives widely used in the diet or applied as auxiliary medicines may increase the risk of adverse interactions with nonsteroidal AIs used in therapy. (Source: Molecules)
Source: Molecules - June 21, 2023 Category: Chemistry Authors: Patr ícia H. A. Bezerra Cristina Amaral Cristina F. Almeida Georgina Correia-da-Silva Maria Regina Torqueti Nat ércia Teixeira Tags: Article Source Type: research
[ASAP] Parahydrogen in Reversible Exchange Induces Long-Lived < sup > 15 < /sup > N Hyperpolarization of Anticancer Drugs Anastrozole and Letrozole
Analytical ChemistryDOI: 10.1021/acs.analchem.2c04817 (Source: Analytical Chemistry)
Source: Analytical Chemistry - May 10, 2023 Category: Chemistry Authors: Keilian MacCulloch, Austin Browning, Patrick TomHon, So ̈ren Lehmkuhl, Eduard Y. Chekmenev, and Thomas Theis Source Type: research
Amalgamation of quercetin with anastrozole and capecitabine: A novel combination to treat breast and colon cancers - An < em > in vitro < /em > study
CONCLUSIONS: The natural compound used in the present study is effective in treating breast and colon cancer at minimal concentrations in combination with the drugs. This combinational treatment appears to be reported for the first time in the present study.PMID:37147989 | DOI:10.4103/jcrt.JCRT_599_20 (Source: Cell Research)
Source: Cell Research - May 6, 2023 Category: Cytology Authors: Mary Shobha Rani Inala Kiranmayee Pamidimukkala Source Type: research
Amalgamation of quercetin with anastrozole and capecitabine: A novel combination to treat breast and colon cancers - An < em > in vitro < /em > study
CONCLUSIONS: The natural compound used in the present study is effective in treating breast and colon cancer at minimal concentrations in combination with the drugs. This combinational treatment appears to be reported for the first time in the present study.PMID:37147989 | DOI:10.4103/jcrt.JCRT_599_20 (Source: Cancer Control)
Source: Cancer Control - May 6, 2023 Category: Cancer & Oncology Authors: Mary Shobha Rani Inala Kiranmayee Pamidimukkala Source Type: research
Cancers, Vol. 15, Pages 2517: Cannabidiol as a Promising Adjuvant Therapy for Estrogen Receptor-Positive Breast Tumors: Unveiling Its Benefits with Aromatase Inhibitors
Conclusions: Contrary to Ana and Let, this study highlights the potential benefits of combining CBD with Exe to improve breast cancer treatment and opens up the possibility of new therapeutic approaches comprising the use of cannabinoids. (Source: Cancers)
Source: Cancers - April 27, 2023 Category: Cancer & Oncology Authors: Cristina Ferreira Almeida Nat ércia Teixeira Maria Jo ão Valente Anne Marie Vinggaard Georgina Correia-da-Silva Cristina Amaral Tags: Article Source Type: research
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
CONCLUSION: Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer.PMID:37079878 | DOI:10.1200/JCO.22.00577 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 20, 2023 Category: Cancer & Oncology Authors: Takuji Iwase Shigehira Saji Kotaro Iijima Kenji Higaki Shoichiro Ohtani Yasuyuki Sato Yasuo Hozumi Yoshie Hasegawa Yasuhiro Yanagita Hiroyuki Takei Maki Tanaka Hideji Masuoka Masahiko Tanabe Chiyomi Egawa Yoshifumi Komoike Toshitaka Nakamura Hiroshi Ohtsu Source Type: research
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
CONCLUSION: Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer.PMID:37079878 | DOI:10.1200/JCO.22.00577 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 20, 2023 Category: Cancer & Oncology Authors: Takuji Iwase Shigehira Saji Kotaro Iijima Kenji Higaki Shoichiro Ohtani Yasuyuki Sato Yasuo Hozumi Yoshie Hasegawa Yasuhiro Yanagita Hiroyuki Takei Maki Tanaka Hideji Masuoka Masahiko Tanabe Chiyomi Egawa Yoshifumi Komoike Toshitaka Nakamura Hiroshi Ohtsu Source Type: research
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
CONCLUSION: Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer.PMID:37079878 | DOI:10.1200/JCO.22.00577 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 20, 2023 Category: Cancer & Oncology Authors: Takuji Iwase Shigehira Saji Kotaro Iijima Kenji Higaki Shoichiro Ohtani Yasuyuki Sato Yasuo Hozumi Yoshie Hasegawa Yasuhiro Yanagita Hiroyuki Takei Maki Tanaka Hideji Masuoka Masahiko Tanabe Chiyomi Egawa Yoshifumi Komoike Toshitaka Nakamura Hiroshi Ohtsu Source Type: research
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
CONCLUSION: Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer.PMID:37079878 | DOI:10.1200/JCO.22.00577 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 20, 2023 Category: Cancer & Oncology Authors: Takuji Iwase Shigehira Saji Kotaro Iijima Kenji Higaki Shoichiro Ohtani Yasuyuki Sato Yasuo Hozumi Yoshie Hasegawa Yasuhiro Yanagita Hiroyuki Takei Maki Tanaka Hideji Masuoka Masahiko Tanabe Chiyomi Egawa Yoshifumi Komoike Toshitaka Nakamura Hiroshi Ohtsu Source Type: research
Identification of non-steroidal aromatase inhibitors via in-silico and in-vitro studies
CONCLUSION: STD-NMR-based epitope mapping indicated close proximity of the alkyl chain followed by an aromatic ring with the receptor (aromatase). These compounds were also found to be non-cytotoxic against human fibroblast cells (BJ cells). Thus, the current study has identified new aromatase inhibitors (compounds 4, and 8) for further pre-clinical and clinical research.PMID:37005533 | DOI:10.2174/1573406419666230330082426 (Source: Medicinal Chemistry)
Source: Medicinal Chemistry - April 3, 2023 Category: Chemistry Authors: Humaira Zafar Rabbia Anis Sana Hafeez Atia-Tul Wahab Maria Aqeel Khan Fatima Zehra Basha Innokenity V Maslennikov M Iqbal Choudhary Source Type: research
